openPR Logo
Press release

Global Clopidogrel Market Share and Growth Factors by 2025 : Pfizer, Dr Reddy’s, Apotex Corp, Roxane Laboratories

07-09-2018 01:55 PM CET | Science & Education

Press release from: TMR Research

Global Clopidogrel Market Share and Growth Factors by 2025 : Pfizer, Dr Reddy’s, Apotex Corp, Roxane Laboratories

Global Clopidogrel Market: Snapshot

Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are in clinical trials. As a result, the drug did not face much competition and has taken over the global market, with its array of application constantly expanding.

The substantial and high-level evidence gathered over the years support the use of Clopidogrel for reduction of mortality and morbidity patients with acute coronary syndrome, myocardial infarction, and a number of other indications. As a result, the drug has developed a formidable presence in the global market over the years. Moreover, the drug’s relative ease of use, low rate of incidence of adverse reactions, and good tolerability have made it the de-facto antiplatelet agent for the reduction of atherosclerotic events in patients.

These factors have helped the global Clopidogrel market to tread along an excellent growth path in the past few years and the market is expected to embark upon a healthy growth path in the next few years as well. However, the overall profitability of the market has reduced to a certain extent owing to entry of a number of generic products post the patent expiry of Clopidogrel manufacture in 2013. Nevertheless, the vast pool of patients prescribed Clopidogrel on an annual basis across the globe will allow market players excellent growth prospects in the next few years.

Request Sample Copy of the Report @

www.tmrresearch.com/sample/sample?flag=B&rep_id=6

Global Clopidogrel Market: Snapshot

Clopidogrel is an antiplatelet agent of thienopyridine, which is primarily used to prevent the blood clots and help against cardiovascular problems associated with the blood clotting. The medications for inhibiting blood clots after a recent heart stroke also use clopidogrel, which is a white colored powder that is insoluble in water at neutral pH but freely soluble at pH1. Clopidogrel was the second most successful drug trailing behind Pfizer’s Lipito in 2010. Sold under the brand name Plavix, and marketed by Sanofi and Bristol-Myers Squibb, the demand for clopidogrel is escalating due to the increasing number of heart attack cases across the globe.

The patent of clopidogrel manufacturing got expires on Market 31, 2012 and is expected to prompt pharmaceutical companies to venture into clopidogrel drug manufacturing. Moreover, companies such as Dr. Reddy’s have acquired the approval to manufacture clopidogrel 300mg. Furthermore, several other organizations such as Roxane Laboratories, Aurobindo Pharma, Sun Pharma, Torrent Pharmaceuticals, and Apotex Crop have gained approval for marketing clopidogrel 75mg. Clopidogrel is also used with aspirin to treat worsening chest pain and to keep blood vessels open and present blood clots after certain heart related operations.

Request TOC of the Report @

www.tmrresearch.com/sample/sample?flag=T&rep_id=6

Global Clopidogrel Market: Trends and Prospects

The primary factor for the increased demand for clopidogrel is the mounting population across the world who are suffering from cardiovascular diseases and related problems. Additionally, the changing lifestyle and increase in number of patients related with cardiovascular diseases among the emerging economies in the Asia Pacific region are also expected to be the major consumers for clopidogrel in the next six years. Moreover, the patent expiry of clopidogrel drug is anticipated to open floodgates for various pharmaceutical companies to venture into production of clopidogrel drug.

According to the World Heart Federation, nearly 15 million people suffer from heart attack or related problems globally. Out of these, roughly six million of these patients die while another five million are disabled permanently. This vast patient base is the primary factor that will sustain the demand during the forecast period.

Read Comprehensive Overview of Report @

www.tmrresearch.com/clopidogrel-market

Global Clopidogrel Market: Geographical Outlook

Currently, North America and Europe contribute to the maximum demand for clopidogrel, owing to factors such as robust healthcare infrastructure and high affordability of the residents in this region. However, several countries in the region of Asia Pacific, such as China, India, and Japan are aggressively working towards improving their healthcare sector with the help of favorable policies by the localized governments and increasing disposable income among the urban population. Asia Pacific is home for nearly half of the world’s population, which makes for a high quantity of patient base. Additionally, these regions also have skilled labor at low cost which is encouraging players in the market to invest actively and tap the unmet demand.

Some of the key players in the global clopidogrel market are Pfizer, Dr Reddy’s, Apotex Corp, Roxane Laboratories, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharma.

The study presents reliable qualitative and quantitative insights into:

Market segments and sub-segments
Market trends and dynamics
Supply and demand chain of the market
Market valuation (revenue and/or volume)
Key trends/opportunities/challenges
Forces defining present and estimated future state of the competitive landscape
Technological developments
Value chain and stakeholder analysis

The regional analysis covers:

North America
Latin America
Europe
Asia Pacific
Middle East and Africa

The vast market research data included in the study is the result of extensive primary and secondary research activities. Surveys, personal interviews, and inputs from industry experts form the crux of primary research activities and data collected from trade journals, industry databases, and reputable paid sources form the basis of secondary research. The report also includes a detailed qualitative and quantitative analysis of the market, with the help of information collected from market participants operating across key sectors of the market value chain. A separate analysis of macro- and micro-economic aspects, regulations, and trends influencing the overall development of the market is also included in the report.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Email: sales@tmrresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Clopidogrel Market Share and Growth Factors by 2025 : Pfizer, Dr Reddy’s, Apotex Corp, Roxane Laboratories here

News-ID: 1116023 • Views: 612

More Releases from TMR Research

Weigh in Motion Market Share and Growth Factors Impact Analysis 2018 – 2028
Weigh in Motion Market – Introduction Weigh in motion (WIM) devices are specifically designed equipment to record the truck axle & gross vehicle weights as they drive over a measuring site or a sensor. The existing weigh in motion systems are witnessing an increasing traction over the conventional static weigh stations, as they don’t require the vehicle to stop, which make them a more efficient option. Numerous benefits of weigh
Gas Analysis Systems Market Competitive Landscape Analysis with Forecast by 2028
Gas Analysis Systems Market Introduction Gas analysis systems are used to monitor or analyze various chemical gases present in the product or sample. It helps in identifying the gas and also provides information on the quantity, displaying in the numerical or graphical form. The standard gas analysis system includes sample probe, line, filter, gas conditioning system including pump, cooler, and calibration gas system, and series of gas analyzers. Industries across sectors
VRF System Market - Product Application 2028 | Commercial Residential Others (Me …
VRF System Market – Introduction Variable refrigerant flow (VRF) system is widely adopted to control the amount of refrigerant flowing to various evaporators with different configurations and capacities. This growing adoption of VRF systems is attributed to their ability to provide comfort without swings at room temperature by offering the desired supply of heating or cooling when the need arises. VRF system caters to various applications owing to its availability
Digital Out of Home Market Dynamic Business Environment during 2018 - 2028
Digital Out of Home Market– Introduction Digital out of home (DOOH), also referred to as digital signage is a modern form of advertising that has effectively replaced traditional forms of advertising and marketing. Digital out of home advertising enables local vendors and advertisers to engage customers in real time, and track and monitor the effectiveness of their marketing messages. DOOH is a rapidly growing and dynamically-served visual mode of advertising

All 25823 Releases


More Releases for Clopidogrel Pharma Reddy’s

Clopidogrel Market - Analysis On Current Trends 2025 | Pfizer, Dr Reddy’s, Apo …
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are
Clopidogrel Market Competitive Analysis by 2025 : Pfizer, Dr Reddy’s, Apotex C …
Global Clopidogrel Market: Snapshot Clopidogrel is an antiplatelet agent of thienopyridine, which is primarily used to prevent the blood clots and help against cardiovascular problems associated with the blood clotting. The medications for inhibiting blood clots after a recent heart stroke also use clopidogrel, which is a white colored powder that is insoluble in water at neutral pH but freely soluble at pH1. Clopidogrel was the second most successful drug trailing
Clopidogrel Market - Top leading manufacturers 2025 | Pfizer, Dr Reddy’s
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are
Clopidogrel Market global Industry Analysis 2017-2025 : Dr Reddy’s, Apotex Cor …
Global Clopidogrel Market: Snapshot Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are